To UM home page

Researcher

Hupperts, R.M.M.

Affiliatie hoogleraar, H/MS

View graph of relations
1 - 50 out of 106Page size: 50
  1. 2019
  2. Published
    Rolf, L., Smolders, J., van den Ouweland, J., Hupperts, R., & Damoiseaux, J. (2019). Correlation of different cellular assays to analyze T cell-related cytokine profiles in vitamin D-3-supplemented patients with multiple sclerosis. Molecular Immunology, 105, 198-204. https://doi.org/10.1016/j.molimm.2018.12.001
  3. 2018
  4. Published
    Diaz, G. M., Hupperts, R., Fraussen, J., & Somers, V. (2018). Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmunity Reviews, 17(12), 1240-1250. https://doi.org/10.1016/j.autrev.2018.07.001
  5. Published
    Rolf, L., Muris, A-H., Mathias, A., Du Pasquier, R., Koneczny, I., Disanto, G., ... Hupperts, R. (2018). Exploring the effect of vitamin D-3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 24(10), 1280-1287. https://doi.org/10.1177/1352458517722646
  6. Published
    Diaz, G. M., Fraussen, J., Van Wijmeersch, B., Hupperts, R., & Somers, V. (2018). Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. Scientific Reports, 8, [8194]. https://doi.org/10.1038/s41598-018-26519-w
  7. Published
    Rolf, L., Damoiseaux, J., Huitinga, I., Kimenai, D., van den Ouweland, J., Hupperts, R., & Smolders, J. (2018). Stress-Axis Regulation by Vitamin D-3 in Multiple Sclerosis. Frontiers in Neurology, 9, [263]. https://doi.org/10.3389/fneur.2018.00263
  8. Published
    Lieben, C. K., Blokland, A., Deutz, N. E., Jansen, W., Han, G., & Hupperts, R. M. (2018). Intake of tryptophan-enriched whey protein acutely enhances recall of positive loaded words in patients with multiple sclerosis. Clinical Nutrition, 37(1), 321-328. https://doi.org/10.1016/j.clnu.2016.12.029
  9. Published
    Rolf, L., Muris, A-H., Theunissen, R., Hupperts, R., Damoiseaux, J., & Smolders, J. (2018). Vitamin D-3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances? Journal of Neuroimmunology, 314, 50-57. https://doi.org/10.1016/j.jneuroim.2017.11.007
  10. Published
    Smolders, J., Hupperts, R., & Damoiseaux, J. (2018). Chapter 8 - The Way Forward With Vitamin D in Multiple Sclerosis. In A. Minagar (Ed.), Neuroinflammation (Second Edition) (pp. 175-191). Academic Press. https://doi.org/10.1016/B978-0-12-811709-5.00009-0
  11. 2017
  12. Published
    Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., ... Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116. https://doi.org/10.1212/WNL.0000000000004313
  13. Published
    Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H-P., Havrdova, E., ... Arnold, D. L. (2017). Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings. Neurology, 89(11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354
  14. Published
    Lorscheider, J., Jokubaitis, V. G., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., ... Kalincik, T. (2017). Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 89(10), 1050-1059. https://doi.org/10.1212/WNL.0000000000004330
  15. Published
    Kalincik, T., Manouchehrinia, A., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., ... MSBase Study Group (2017). Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 140(9), 2426-2443. https://doi.org/10.1093/brain/awx185
  16. Published
    Smolders, J., Rolf, L., Damoiseaux, J., & Hupperts, R. (2017). On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 379, 331-331. https://doi.org/10.1016/j.jns.2017.06.009
  17. Published
    Rolf, L., Muris, A-H., Bol, Y., Damoiseaux, J., Smolders, J., & Hupperts, R. (2017). Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression. Journal of the Neurological Sciences, 378, 30-35. https://doi.org/10.1016/j.jns.2017.04.017
  18. Published
    de Jong, H. J. I., Kingwell, E., Shirani, A., Tervaert, J. W. C., Hupperts, R., Zhao, Y., ... British Columbia Multiple Sclerosi (2017). Evaluating the safety of beta-interferons in MS A series of nested case-control studies. Neurology, 88(24), 2310-2320. https://doi.org/10.1212/WNL.0000000000004037
  19. Published
    Hoogerwerf, A. E. W., Bol, Y., Lobbestael, J., Hupperts, R., & van Heugten, C. M. (2017). Mindfulness-based cognitive therapy severely fatigued multiple sclerosis patients: A waiting list controlled study. Journal of Rehabilitation Medicine, 49(6), 497–504. https://doi.org/10.2340/16501977-2237
  20. Published
    Iaffaldano, P., Simone, M., Lucisano, G., Ghezzi, A., Coniglio, G., Morra, V. B., ... Trojano, M. (2017). Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology, 81(5), 729-739. https://doi.org/10.1002/ana.24938
  21. Published
    Kalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C. M., ... Grp, MSB. S. (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, 16(4), 271-281. https://doi.org/10.1016/S1474-4422(17)30007-8
  22. Published
    Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468
  23. Published
    Knippenberg, S., Smolders, J., van den Maegdenbergh, M., Porro, G., Damoiseaux, J., & Hupperts, R. (2017). Response to "Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis" by Knippenberg et al. Multiple Sclerosis Journal, 23(1), 129-129. https://doi.org/10.1177/1352458516652951
  24. Published
    Knippenberg, S., Smolders, J., van den Maegdenbergh, M., Porro, G., Damoiseaux, J., & Hupperts, R. (2017). Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis. Multiple Sclerosis Journal, 23(1), 128-129. https://doi.org/10.1177/1352458516652950
  25. 2016
  26. Published
    Claes, N., Fraussen, J., Vanheusden, M., Hellings, N., Stinissen, P., Van Wijmeersch, B., ... Somers, V. (2016). Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. Journal of Immunology, 197(12), 4576-4583. https://doi.org/10.4049/jimmunol.1502448
  27. Published
    Fraussen, J., Claes, N., Van Wijmeersch, B., van Horssen, J., Stinissen, P., Hupperts, R., & Somers, V. (2016). B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clinical Immunology, 173, 124-132. https://doi.org/10.1016/j.clim.2016.10.001
  28. Published
    Muris, A-H., Smolders, J., Rolf, L., Thewissen, M., Hupperts, R., & Damoiseaux, J. (2016). Immune regulatory effects of high dose vitamin D-3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFN beta; the SOLARIUM study. Journal of Neuroimmunology, 300, 47-56. https://doi.org/10.1016/j.jneuroim.2016.09.018
  29. Published
    Gasperini, C., Hupperts, R., Lycke, J., Short, C., McNeill, M., Zhong, J., & Mehta, L. R. (2016). Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. Journal of the Neurological Sciences, 370, 123-131. https://doi.org/10.1016/j.jns.2016.08.052
  30. Published
    Muris, A-H., Rolf, L., Broen, K., Hupperts, R., Damoiseaux, J., & Smolders, J. (2016). A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. Journal of Steroid Biochemistry and Molecular Biology, 164, 254-257. https://doi.org/10.1016/j.jsbmb.2015.11.009
  31. Published
    CARE-MS I and CARE-MS II Coinvestigators (2016). Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology, 87(14), 1464-1472. https://doi.org/10.1212/WNL.0000000000003169
  32. Published
    Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., ... Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery and Psychiatry, 87(10), 1133-1137. https://doi.org/10.1136/jnnp-2016-313760
  33. Published
    Benefit study group (2016). The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology, 87(10), 978-987. https://doi.org/10.1212/WNL.0000000000003078
  34. Published
    Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., ... Kalincik, T. (2016). Defining secondary progressive multiple sclerosis. Brain, 139, 2395-2405. https://doi.org/10.1093/brain/aww173
  35. Published
    LaGanke, C., De Seze, J., Freedman, M. S., Habek, M., Hupperts, R. M. M., Limmroth, V., ... Havrdova, E. (2016). Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II). Multiple Sclerosis Journal, 22, 327-328.
  36. Published
    Rolf, L., Damoiseaux, J., Hupperts, R., Huitinga, I., & Smolders, J. (2016). Network of nuclear receptor ligands in multiple sclerosis: Common pathways and interactions of sex-steroids, corticosteroids and vitamin D-3-derived molecules. Autoimmunity Reviews, 15(9), 900-910. https://doi.org/10.1016/j.autrev.2016.07.002
  37. Published
    Brandt-Wouters, E., Gerlach, O. H. H., & Hupperts, R. M. M. (2016). The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. International Journal of Gynecology & Obstetrics, 134(2), 194-196. https://doi.org/10.1016/j.ijgo.2016.01.008
  38. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., ... Trojano, M. (2016). Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis. Annals of Neurology, 80(1), 89-100. https://doi.org/10.1002/ana.24682
  39. Published
    Muris, A-H., Smolders, J., Rolf, L., Klinkenberg, L. J. J., van der Linden, N., Meex, S., ... Hupperts, R. (2016). Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up. PLOS ONE, 11(6), [e0156122]. https://doi.org/10.1371/journal.pone.0156122
  40. Published
    Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Butzkueven, H. (2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 6(2), 102-115. https://doi.org/10.1212/CPJ.0000000000000227
  41. Published
    INFORMS study investigators (2016). Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, 387(10023), 1075-1084. https://doi.org/10.1016/S0140-6736(15)01314-8
  42. Published
    Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group, & Hupperts, R. (2016). Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study. Neurology, 86(10), 920-930. https://doi.org/10.1212/WNL.0000000000002441
  43. Published
    Rolf, L., Muris, A-H., Hupperts, R., & Damoiseaux, J. (2016). Illuminating vitamin D effects on B cells - the multiple sclerosis perspective. Immunology, 147(3), 275-284. https://doi.org/10.1111/imm.12572
  44. Published
    Jongen, P. J., Lemmens, W. A., Hupperts, R., Hoogervorst, E. L. J., Schrijver, H. M., Slettenaar, A., ... Donders, R. (2016). Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines. Patient Preference and Adherence, 10, 909-917. https://doi.org/10.2147/PPA.S108121
  45. 2015
  46. Published
    Kalincik, T., Cutter, G., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., ... Butzkueven, H. (2015). Defining reliable disability outcomes in multiple sclerosis. Brain, 138. https://doi.org/10.1093/brain/awv258
  47. Published
    Bayas, A., Ouallet, J. C., Kallmann, B., Hupperts, R., Fulda, U., & Marhardt, K. (2015). Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery, 12(8), 1239-1250. https://doi.org/10.1517/17425247.2015.1057567
  48. Published
    Kalincik, T., Jokubaitis, V., Izquierdo, G., Duquette, P., Girard, M., Grammond, P., ... Butzkueven, H. (2015). Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 21(9), 1159-1171. https://doi.org/10.1177/1352458514559865
  49. Published
    Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., ... Lechner-Scott, J. (2015). Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLOS ONE, 10(6), [e0122686]. https://doi.org/10.1371/journal.pone.0122686
  50. Published
    Bergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., Grand'Maison, F., ... Trojano, M. (2015). BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 22(6), 981-989. https://doi.org/10.1111/ene.12696
  51. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., ... Trojano, M. (2015). Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2(5), 479-491. https://doi.org/10.1002/acn3.187
  52. Published
    Spelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., ... Butzkueven, H. (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387. https://doi.org/10.1002/acn3.180
  53. Published
    He, A., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., ... Kalincik, T. (2015). Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 72(4), 405-413. https://doi.org/10.1001/jamaneurol.2014.4147
  54. Published
    Peelen, E., Muris, A. H., Damoiseaux, J., Knippenberg, S., Broens, K., Smolders, J., ... Thewissen, M. (2015). GM-CSF production by CD4+ T cells in MS patients: Regulation by regulatory T cells and vitamin D. Journal of Neuroimmunology, 280, 36-42. https://doi.org/10.1016/j.jneuroim.2015.02.007
  55. Published
    Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., ... Butzkueven, H. (2015). Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis. Annals of Neurology, 77(3), 425-435. https://doi.org/10.1002/ana.24339
Previous 1 2 3 Next

UM personal profile

UM postal address
P.O. Box 616
6200 MD Maastricht
The Netherlands

UM visiting address
Minderbroedersberg 4-6
6211 LK Maastricht
The Netherlands
Phone: +31 43 388 2222

Quick Links